P
ABCL icon

&Partners’s AbCellera Biologics ABCL Stock Holding History

&Partners’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.5K Hold
10,000
– – ﹤0.01% 2479
2026
Q1 		$34.9K Hold
10,000
– – ﹤0.01% 2372
2025
Q4 		$34.2K Sell
10,000
-5,000
-33% -$22.3K ﹤0.01% 2252
2025
Q3 		$75.5K Buy
+15,000
New +$66.1K ﹤0.01% 2065

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

&Partners's ABCL Position: Q2 2026 in Review

&Partners held its AbCellera Biologics (ABCL) position steady in Q2 2026 at 10,000 shares worth $78.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2479.

&Partners first reported a position in ABCL in Q3 2025 and has held it in 4 quarters since. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • &Partners held 10,000 shares of AbCellera Biologics worth $78.5K as of Q2 2026.
  • &Partners left its AbCellera Biologics share count unchanged in Q2 2026.
  • AbCellera Biologics made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2479 holding.
  • &Partners first reported a position in AbCellera Biologics in Q3 2025 and has held it in 4 quarters since.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.